{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:49:35Z","timestamp":1788623375360,"version":"build-2803163510"},"reference-count":27,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Establishing comparability between measured outcomes in clinical trials poses a significant obstacle for systematic reviewers. Core outcome sets (COSs) were developed to address this issue. The macular degeneration (MD) COS is designed to standardise outcome measurement across clinical trials for MD. This study investigates the uptake of the MD COS in standardising outcome measurement across clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional analysis<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a search on ClinicalTrials.gov to locate MD clinical trials that were registered 5 years prior to COS publication through the search date of 26 June 2023 and obtained a pool of 2152 registered studies. After applying various inclusion and exclusion criteria, we analysed 159 trials. We then analysed the COS uptake using an interrupted time series analysis (ITSA) and performed performed analyses of variance (ANOVAs) and Pearson correlations to evaluate associations between trial characteristics and outcome measurement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ITSA showed no significant change in uptake following the MD COS (2016): mean percentage of completion of the COS increased by 0.24% per month before publication (p=0.27) and by 0.07% per month after publication (p=0.62), indicating no meaningful post-publication slope change in COS use. For context, visual acuity was most commonly measured, while several patient-reported and disutility domains were infrequently captured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>No discernible patterns in COS usage for MD trials were observed. We recommend further collaboration between regulators and COS developers to help with COS uptake. Additionally, we suggest that further studies analyse adherence to COSs in respect to regulatory recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-104705","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T06:10:49Z","timestamp":1766643049000},"page":"e104705","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing uptake of the macular degeneration core outcome set in clinical trials: a cross-sectional study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8177-9153","authenticated-orcid":false,"given":"Eli","family":"Oldham","sequence":"first","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Hunter","family":"Hall","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Jones","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Modi","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaelyn","family":"Ward","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Magee","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Magana","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffin","family":"Hughes","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia Ito","family":"Ford","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Vassar","sequence":"additional","affiliation":[{"name":"Oklahoma State University Center for Health Sciences, Tulsa, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2026010703500067000_15.12.e104705.1","article-title":"Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment","volume":"14","author":"Vyawahare","year":"2022","journal-title":"Cureus"},{"key":"2026010703500067000_15.12.e104705.2","unstructured":"National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, et al . The Impact of Vision Loss. National Academies Press (US), 2016."},{"key":"2026010703500067000_15.12.e104705.3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100852","article-title":"Global economic productivity losses from vision impairment and blindness","volume":"35","author":"Marques","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2026010703500067000_15.12.e104705.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.01.011"},{"key":"2026010703500067000_15.12.e104705.5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1590\/S1413-35552007000100013","article-title":"Systematic review studies: a guide for careful synthesis of the scientific evidence","volume":"11","author":"Sampaio","year":"2007","journal-title":"Braz J Phys Ther"},{"key":"2026010703500067000_15.12.e104705.6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamaophthalmol.2017.2583","article-title":"Comparison of Clinical Trial and Systematic Review Outcomes for the 4 Most Prevalent Eye Diseases","volume":"135","author":"Saldanha","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2026010703500067000_15.12.e104705.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109400","article-title":"Outcomes in Cochrane systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability","volume":"9","author":"Saldanha","year":"2014","journal-title":"PLoS One"},{"key":"2026010703500067000_15.12.e104705.8","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010703500067000_15.12.e104705.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.01.004"},{"key":"2026010703500067000_15.12.e104705.10","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-312117"},{"key":"2026010703500067000_15.12.e104705.11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.04.012","article-title":"Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration","volume":"168","author":"Rodrigues","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2026010703500067000_15.12.e104705.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j2262","article-title":"A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis","volume":"357","author":"Kirkham","year":"2017","journal-title":"BMJ"},{"key":"2026010703500067000_15.12.e104705.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLoS Med"},{"key":"2026010703500067000_15.12.e104705.14","unstructured":"Magee T , Jones G , Magana K , et al . OSF. Available: https:\/\/osf.io\/s8zxw\/ [Accessed 13 Jul 2023]."},{"key":"2026010703500067000_15.12.e104705.15","unstructured":"COMET initiative. Available: https:\/\/www.comet-initiative.org\/About\/History [Accessed 17 Jul 2023]."},{"key":"2026010703500067000_15.12.e104705.16","unstructured":"COMET initiative. Available: https:\/\/www.comet-initiative.org\/Resources\/COSTutorial [Accessed 10 Jul 2023]."},{"key":"2026010703500067000_15.12.e104705.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET Handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"key":"2026010703500067000_15.12.e104705.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.10.012"},{"key":"2026010703500067000_15.12.e104705.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036562","article-title":"Assessing the relevance and uptake of core outcome sets (an agreed minimum collection of outcomes to measure in research studies) in Cochrane systematic reviews: a review","volume":"10","author":"Williamson","year":"2020","journal-title":"BMJ Open"},{"key":"2026010703500067000_15.12.e104705.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181066"},{"key":"2026010703500067000_15.12.e104705.21","unstructured":"Center for drug evaluation, research. clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (ra). US Food and Drug Administration; 2020. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-development-programs-drugs-devices-and-biological-products-treatment-rheumatoid-arthritis [Accessed 14 Jul 2023]."},{"key":"2026010703500067000_15.12.e104705.22","unstructured":"Clinical investigation of medicinal products for treatment of rheumatoid arthritis - scientific guideline. European Medicines Agency; 2018. Available: https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis-scientific-guideline [Accessed 14 Jul 2023]."},{"key":"2026010703500067000_15.12.e104705.23","unstructured":"EMA . Clinical investigation of medicinal products used in the treatment of osteoarthritis - scientific guideline. European Medicines Agency; 2018. Available: https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-used-treatment-osteoarthritis-scientific-guideline [Accessed 14 Jul 2023]."},{"key":"2026010703500067000_15.12.e104705.24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jclinepi.2019.07.007","article-title":"Industry funding was associated with increased use of core outcome sets","volume":"115","author":"Kirkham","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2026010703500067000_15.12.e104705.25","first-page":"295","article-title":"The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication","volume":"107","author":"Schott","year":"2010","journal-title":"Dtsch Arztebl Int"},{"key":"2026010703500067000_15.12.e104705.26","unstructured":"Center for drug evaluation, research. neovascular age-related macular degeneration: developing drugs for treatment. US Food and Drug Administration; 2023. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/neovascular-age-related-macular-degeneration-developing-drugs-treatment [Accessed 11 Jul 2023]."},{"key":"2026010703500067000_15.12.e104705.27","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22339"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-104705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:54:23Z","timestamp":1767786863000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-104705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,24]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-104705"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-104705","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}